Estarylla

Birth Control, Acne Vulgaris, Folate supplementation therapy + 5 more
Treatment
1 FDA approval
20 Active Studies for Estarylla

What is Estarylla

EthinylestradiolThe Generic name of this drug
Treatment SummaryEthinylestradiol is an estrogen medication that was first developed in 1938. It was created to increase its oral bioavailability and was approved by the FDA in 1943. It is most commonly used in contraceptive pills and replaced mestranol as the active ingredient.
LOESTRIN Fe 1.5/30is the brand name
image of different drug pills on a surface
Estarylla Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
LOESTRIN Fe 1.5/30
Ethinylestradiol
1973
679

Approved as Treatment by the FDA

Ethinylestradiol, also known as LOESTRIN Fe 1.5/30, is approved by the FDA for 1 uses including Birth Control .
Birth Control
Used to treat Contraception in combination with Levonorgestrel

Effectiveness

How Estarylla Affects PatientsEthinylestradiol is a synthetic form of the female hormone estrogen that helps to prevent ovulation. Taking ethinylestradiol once a day is usually enough to produce long-lasting effects, and it is considered to be a relatively safe drug with few serious side effects. However, patients should be aware of the risk of thrombotic events.
How Estarylla works in the bodyEthinylestradiol is a synthetic hormone used in combined oral contraceptives. It works by suppressing ovulation, thickening the cervical mucus, and preventing implantation of a fertilized egg in the uterus. It also reduces luteinizing hormone and increases sex hormone binding globulin. This helps to reduce bone density.

When to interrupt dosage

The extent of Estarylla is reliant upon the determined condition, including Acne Vulgaris, Hormonal Contraception and Folate supplementation therapy. The measure of dosage is dependent upon the method of administration delineated in the table hereunder.
Condition
Dosage
Administration
Folate supplementation therapy
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Insert, extended release - Vaginal, Vaginal, Ring - Vaginal, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Ring, Patch - Transdermal, Capsule, Capsule - Oral
Acne Vulgaris
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Insert, extended release - Vaginal, Vaginal, Ring - Vaginal, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Ring, Patch - Transdermal, Capsule, Capsule - Oral
Osteoporosis
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Insert, extended release - Vaginal, Vaginal, Ring - Vaginal, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Ring, Patch - Transdermal, Capsule, Capsule - Oral
Menopause
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Insert, extended release - Vaginal, Vaginal, Ring - Vaginal, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Ring, Patch - Transdermal, Capsule, Capsule - Oral
Birth Control
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Insert, extended release - Vaginal, Vaginal, Ring - Vaginal, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Ring, Patch - Transdermal, Capsule, Capsule - Oral
Acne Vulgaris
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Insert, extended release - Vaginal, Vaginal, Ring - Vaginal, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Ring, Patch - Transdermal, Capsule, Capsule - Oral
Hormonal Contraception
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Insert, extended release - Vaginal, Vaginal, Ring - Vaginal, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Ring, Patch - Transdermal, Capsule, Capsule - Oral
Patient desires oral contraception for birth control
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Insert, extended release - Vaginal, Vaginal, Ring - Vaginal, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Ring, Patch - Transdermal, Capsule, Capsule - Oral

Warnings

Estarylla has twenty-six contraindications, so it should not be consumed when encountering any of the conditions laid out in the following table.Estarylla Contraindications
Condition
Risk Level
Notes
Smoking
Do Not Combine
Metrorrhagia
Do Not Combine
estrogen-sensitive cancer
Do Not Combine
Thrombophlebitis
Do Not Combine
Venous Thrombosis
Do Not Combine
Venous Thrombosis
Do Not Combine
Pulse Frequency
Do Not Combine
Breast
Do Not Combine
Coronary Artery Disease
Do Not Combine
high risk of arterial thrombotic disease
Do Not Combine
Thromboembolism
Do Not Combine
Coronary Disease
Do Not Combine
Hypersensitivity
Do Not Combine
Pulse Frequency
Do Not Combine
Adrenal Insufficiency
Do Not Combine
major surgery with prolonged immobilization
Do Not Combine
Pulse Frequency
Do Not Combine
Hypertension
Do Not Combine
undiagnosed abnormal genital bleeding
Do Not Combine
Breast Cancer
Do Not Combine
Liver Neoplasms
Do Not Combine
Deep Vein Thrombosis
Do Not Combine
Fibrosis
Do Not Combine
Breast
Do Not Combine
Renal Insufficiency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Ethinylestradiol may interact with Pulse Frequency
There are 20 known major drug interactions with Estarylla.
Common Estarylla Drug Interactions
Drug Name
Risk Level
Description
Anastrozole
Major
The therapeutic efficacy of Anastrozole can be decreased when used in combination with Ethinylestradiol.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Ethinylestradiol.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Ethinylestradiol.
Belinostat
Major
The metabolism of Belinostat can be increased when combined with Ethinylestradiol.
Binimetinib
Major
The metabolism of Binimetinib can be increased when combined with Ethinylestradiol.
Estarylla Toxicity & Overdose RiskWomen who overdose on the drug may experience symptoms such as irregular menstrual bleeding, nausea, vomiting, breast tenderness, abdominal pain, drowsiness, and fatigue. Treatment for an overdose includes providing symptomatic and supportive care, including monitoring potassium and sodium levels, and watching for signs of metabolic acidosis.
image of a doctor in a lab doing drug, clinical research

Estarylla Novel Uses: Which Conditions Have a Clinical Trial Featuring Estarylla?

38 active studies are underway to assess the effectiveness of Estarylla in providing Folate supplementation therapy, Premenstrual Dysphoric Disorder and Menopausal symptom relief.
Condition
Clinical Trials
Trial Phases
Birth Control
22 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2
Hormonal Contraception
0 Actively Recruiting
Folate supplementation therapy
0 Actively Recruiting
Patient desires oral contraception for birth control
0 Actively Recruiting
Osteoporosis
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Menopause
0 Actively Recruiting

Estarylla Reviews: What are patients saying about Estarylla?

5Patient Review
6/17/2022
Estarylla for Premenstrual Disorder with a State of Unhappiness
I had great success with estarylla, and I recommend it to other women who suffer from PMDD. It really helped regulate my mood swings and suicidal thoughts during that time of the month. Plus, there were no negative side effects that I could see, except for a slight decrease in appetite.
5Patient Review
12/29/2021
Estarylla for Birth Control
Estrella has been life-changing for me. Not only did it help with my acne, but it also allowed me to wean myself off of my antidepressants. I haven't felt this stable in years!
5Patient Review
12/14/2021
Estarylla for Birth Control
I've had no issues taking this medication for an entire year, which is great because it means I haven't experienced any negative side effects. The only issue I had was some spotting the first month, but that quickly resolved itself.
5Patient Review
1/26/2022
Estarylla for Birth Control
I had some manageable side effects when I first started taking this medication, but they went away after a few weeks. I'm really glad I decided to try it out, despite the negative reviews I'd read online.
5Patient Review
2/24/2022
Estarylla for Birth Control
I switched from a different birth control pill (Mono-Linyah) to this one, and they are really similar. The first few days, I was more emotionally sensitive at night (crying/angry), but it soon passed and I feel great! This pill also helped with my anxiety.
2.3Patient Review
3/30/2022
Estarylla for Abnormally Long or Heavy Periods
I will be discontinuing my usage of estarylla after just two weeks. I have experienced the worst acne breakouts of my life, as well as headaches, nausea, and severe cramps during my last period while on this medication. This is by far the worst birth control I have ever used!
2Patient Review
4/17/2022
Estarylla for Painful Periods
I've been taking birth control pills for years, but this is the first time I experienced such incredibly painful cramps and heavy bleeding that started on only the third day of my period. It's now been eight days and I'm struggling to get through each day. A variety of pain medications haven't helped at all. If I had known about these potential side effects, I never would have started taking these pills.
2Patient Review
1/18/2022
Estarylla for Birth Control
I switched from my original Tri-lo sprintec to try this one, and had the WORST experience ever. I was terrified after reading the reviews and can say that my experience lined up with most of them. I had terrible nausea for a week straight. i took the pills for 6 days in total and had to stop because my nausea was making me unable to eat and drink. Worst experience ever!!!
1.7Patient Review
3/23/2022
Estarylla for Abnormally Long or Heavy Periods
My second Mirena insertion was in March 2021. I generally don't experience periods with birth control, but this time I had one that was very heavy with clots. So, my doctor prescribed Estarylla to help reduce the heavy bleeding. While it did reduce the heavy bleeding, it also extended the amount of time between cycles.
1Patient Review
8/17/2022
Estarylla for Birth Control
Over time, this treatment became more and more ineffective, to the point where it was actually causing me a great deal of harm. I suffered from migraines with aura, headaches, chest pain, anxiety, skin problems, back spasms... the list goes on.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about estarylla

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Estarylla generic for?

"A birth control pill that has three different doses of active ingredients that are taken over the course of a 28-day cycle."

Answered by AI

What are the side effects of Estarylla?

"The following side effects may occur: nausea, vomiting, headache, bloating, breast tenderness, swelling of the ankles/feet (fluid retention), or weight change. Vaginal bleeding between periods (spotting) or missed/irregular periods may also occur, especially during the first few months of use."

Answered by AI

What kind of birth control is Estarylla?

"The Estarylla birth control pill contains female hormones that prevent ovulation. Estarylla also changes cervical mucus and the uterine lining, making it harder for sperm to reach the uterus and harder for a fertilized egg to attach to the uterus."

Answered by AI

Is Estarylla a strong birth control?

"Even though Estarylla is effective, birth control pills in general are only 99.7% effective if used perfectly and 93% effective in regular use."

Answered by AI

Clinical Trials for Estarylla

Image of University of California, San Diego in La Jolla, United States.

Lidocaine for Pain Control in Birth Control

18 - 50
Female
La Jolla, CA
The goal of this research study is to learn more about how different uses of a numbing medication might affect pain levels while getting an IUD placed. The investigators are also studying participants opinions of their clinicians' empathy. The investigators are inviting patients who arrive at their clinic visit seeking an IUD. Usually, at University of California, San Diego (UCSD), for patients who have never delivered a baby, clinicians use a buffered paracervical block for before IUD placement. The purpose of this research study is to investigate whether a "buffered" (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) paracervical block (numbing medication given on both sides of the cervix) is effective in reducing pain during IUD placement in individuals with prior C-sections, the difference between buffered and unbuffered for nulliparous patients, and whether a medicated gel reduces pain with the paracervical block.
Recruiting
Paid Trial
University of California, San DiegoSheila K Mody, MD, MPH
Image of EmpoweRx, Inc in Del Mar, United States.

HAPPI Software for Birth Control Access

18+
All Sexes
Del Mar, CA
The goal of this clinical trial is to learn if use of the HAPPI software can improve pharmacist-provided birth control services. The main questions it aims to answer are: 1. Does the HAPPI software make it easier for pharmacists to provide birth control services in their pharmacy? 2. Does the HAPPI software make it easier for patients to access birth control? Researchers will compare pharmacists' implementation and patients' access when using the HAPPI software and when not using the HAPPI software to see if the software improves implementation and access. Participants will include pharmacists and patients. Pharmacists will be asked to provide birth control services as normal while using the HAPPI software. Patients will be asked to receive birth control services from a pharmacist as normal, while using the HAPPI software.
Recruiting
Has No Placebo
EmpoweRx, Inc
Image of Calabasas Pharmacy in Calabasas, United States.

Electronic Health Record Platform for Birth Control

18 - 51
Female
Calabasas, CA
Hormonal contraceptives are medications that require a prescription, traditionally from a physician or advanced practice provider. Over the past decade, pharmacists have gained the authority to prescribe contraceptives in many states, allowing patients to access these medications directly in pharmacies without first seeing another healthcare provider. The Pharmacist Resource to Implement Services as Modules (PRISM) is an Electronic Health Record platform designed to streamline workflows and provide clinical decision support, making it easier and safer to deliver clinical services in community pharmacies. This pilot study will evaluate patient-reported outcomes for women receiving contraceptive services from pharmacists using the PRISM platform at five community pharmacies across the United States over a 12-week period. The study will assess the quality of care, contraception continuation and failure rates, side effect rates, preventative healthcare utilization, and overall patient experience with pharmacy contraceptive services.
Waitlist Available
Has No Placebo
Calabasas Pharmacy (+4 Sites)OvaryIt, LLC
Have you considered Estarylla clinical trials? We made a collection of clinical trials featuring Estarylla, we think they might fit your search criteria.Go to Trials
Image of Jackson State University/Department of Behavioral & Environmental Health in Jackson, United States.

PEN-3 Intervention for Postpartum Depression

18 - 45
Female
Jackson, MS
Maternal mortality in the United States is higher than in peer nations and has not decreased since 1990. Beyond mortality, severe maternal mortality impacts far too many women. Not only are these high rates alarming, but notable racial/ethnic and socioeconomic disparities exist. These inequities are highly regional, with women living in the rural southeast part of the United States, including the Mississippi Delta, having the highest rates of maternal mortality and morbidity. Unfortunately, these disparities have proven to be stubbornly resistant to interventions, necessitating an innovative multifaceted approach focused on community practice, building trust, and prioritizing patient voices. To meet this need, this proposal aims to establish the Mississippi Delta Research Center of Excellence for Maternal Health with the goal of addressing preventable maternal mortality, decreasing severe maternal morbidity, and promoting maternal health equity in partnership with the Mississippi Delta community. This patient-clinical linkages intervention study will evaluate the effectiveness of a multilevel and multisector communication and health literacy strategy to increase trust and engagement in postpartum healthcare among women in the Mississippi Delta, with a specific focus on Black women, their families, and their communities. These research projects both have the overarching goal of partnering with the community to determine and meet the needs of pregnant and postpartum women in the Mississippi Delta and address the disparities within maternity health and health care outcomes.
Recruiting
Has No Placebo
Jackson State University/Department of Behavioral & Environmental HealthMary Shaw, PhD
Image of University of Colorado Anschutz Medical Campus in Aurora, United States.

Birth Control Pills and DNA Interaction

18 - 45
Female
Aurora, CO
The goal of this clinical trial is to evaluate how differences in specific parts of our DNA can influence how individual bodies break down the hormones contained within oral contraceptive pills, which could affect how well these birth control pills work to prevent pregnancy. The investigators are also interested in exploring how these differences in our DNA can also explain why patients taking the exact same formulation of birth control pill will experience very different side effects. The main questions it aims to answer are: * Do individuals with the CYP3A7\*1C variant have increased metabolism of both desogestrel and ethinyl estradiol when taking a combined oral contraceptive pill? * Do individuals with the CYP3A7\*1C variant experience higher rates of breakthrough ovulation while taking a desogestrel/ethinyl estradiol combined oral contraceptive pill? * What novel genetic loci are associated with alterations in steroid hormone pharmacokinetics and pharmacodynamics among a larger cohort of combined oral contraceptive pill users? Participants will take a specific formulation of combined oral contraceptive pill (desogestrel/ethinyl estradiol) and undergo the following procedures: * Blood draw to measure the amount of progestin and estrogen in their system from the combined oral contraceptive pill * Questionnaires to assess side effects possibly caused by the combined oral contraceptive pill * Blood draw to measure endogenous hormone levels and biomarkers that may be affected by the combined oral contraceptive pill * A transvaginal ultrasound to measure any ovarian follicles (optional procedure)
Phase 4
Recruiting
University of Colorado Anschutz Medical Campus (+2 Sites)Aaron M Lazorwitz, MD, PhD
Have you considered Estarylla clinical trials? We made a collection of clinical trials featuring Estarylla, we think they might fit your search criteria.Go to Trials
Image of Greater Boston Health Center in Boston, United States.

SBIRT for Alcohol and Substance Use Disorders

18+
All Sexes
Boston, MA
The goal of this clinical trial is to test the effectiveness of evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) among adult patients who screen positive to one or more risky alcohol or substance use behaviors while seeking care at a sexual and reproductive health (SRH) clinic. The main questions it aims to answer are: * Does SBIRT impact patients' alcohol and substance use, SRH, mental health, physical health, quality of life, and wellbeing? * Does SBIRT effectiveness differ by ethnicity, socioeconomic status, age, gender, and urbanicity? * Does SBIRT effectiveness differ by delivery mode (in-person vs. telemedicine)? Participants will receive in-person and telemedicine SBIRT, or usual care. Participants will complete surveys at interviews at baseline, 30 days, and 3 months. Researchers will compare patients who received SBIRT to patients who receive usual care to see if patients who receive the SBIRT intervention have a greater reduction in negative outcomes as compared to those who receive usual care. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.
Recruiting
Has No Placebo
Greater Boston Health Center (+3 Sites)Kelli S Hall, MD
Image of OHSU in Portland, United States.

Progestin Contraceptives for Birth Control Effects

18 - 40
Female
Portland, OR
The purpose of the study is to learn more about menstrual changes in progestin contraception users. The investigators are hoping to find out what changes in the endometrium lead to different bleeding patterns during the first year of progestin contraception use. Participants will choose to receive the contraceptive implant (Etonogestrel implant also called Nexplanon) or the contraceptive injectable (Depo-medroxyprogesterone acetate (DMPA) also called Depo-Provera) for up to 12 months. They will be asked to have 4 endometrial biopsies over the course of the study, as well as blood draws, physical exams, and pregnancy tests. Participants will also use a daily text message or email diary to report bleeding patterns. This study's plan is to comprehensively phenotype bleeding patterns and profile the entire endometrium using single-cell RNA seq data (sCRNAseq).
Phase < 1
Recruiting
OHSUAlison Edelman, MD
Have you considered Estarylla clinical trials? We made a collection of clinical trials featuring Estarylla, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security